Infliximab biosimilar (Nichiiko/Aprogen)

英夫利西单抗生物类似药 (Nichiiko/Aprogen)

Report date: 2022/03/16 10:40:26

Base Information

Drug NameInfliximab biosimilar (Nichiiko/Aprogen)
Drug Alias Name英夫利西单抗生物仿制药 (Nichiiko/Aprogen)NI-071GS-071GS-07AP-07
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionTumor necrosis factor α inhibitors
TargetsTumor necrosis factor α
Therapy Area/IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[5] 
Global Approved IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2017/09/27
Country/TerritoryCzechiaUnited StatesUkraine +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAprogenNichi-Iko Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNichi-Iko Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPsoriasisCrohn DiseaseColitis, Ulcerative +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL04AB02
Related LinksN/A